Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.56 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16583229 | 1.00 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL16583499 | 0.92 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL15812940 | 0.90 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL16583405 | 0.90 | PIK3R2 (0.55) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL15864460 | 0.89 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL16583322 | 0.89 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL16583221 | 0.88 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL17335271 | 0.87 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL22039327 | 0.87 | PIK3R2 (0.51) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL18188636 | 0.87 | PIK3R2 (0.51) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | HDAC1, HDAC3, HDAC4 | PIK3CD 17/4885PIK3CG 24/4885PIK3R2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.